KR100373948B1 - 호산성과립구의병적인과반응성을감소시키기위한크산틴유도체를포함하는약제학적조성물,신규한크산틴화합물및이의제조방법 - Google Patents

호산성과립구의병적인과반응성을감소시키기위한크산틴유도체를포함하는약제학적조성물,신규한크산틴화합물및이의제조방법 Download PDF

Info

Publication number
KR100373948B1
KR100373948B1 KR1019960705541A KR19960705541A KR100373948B1 KR 100373948 B1 KR100373948 B1 KR 100373948B1 KR 1019960705541 A KR1019960705541 A KR 1019960705541A KR 19960705541 A KR19960705541 A KR 19960705541A KR 100373948 B1 KR100373948 B1 KR 100373948B1
Authority
KR
South Korea
Prior art keywords
formula
methyl
compound
xanthine
ethyl
Prior art date
Application number
KR1019960705541A
Other languages
English (en)
Korean (ko)
Other versions
KR970702044A (ko
Inventor
울리히 게베르트
히리스토 아나그노스토풀로스
클라우스 크로에겔
알렉산더 카프
Original Assignee
훽스트 악티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 훽스트 악티엔게젤샤프트 filed Critical 훽스트 악티엔게젤샤프트
Publication of KR970702044A publication Critical patent/KR970702044A/ko
Application granted granted Critical
Publication of KR100373948B1 publication Critical patent/KR100373948B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1019960705541A 1994-04-05 1995-03-21 호산성과립구의병적인과반응성을감소시키기위한크산틴유도체를포함하는약제학적조성물,신규한크산틴화합물및이의제조방법 KR100373948B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4411660A DE4411660A1 (de) 1994-04-05 1994-04-05 Verwendung von Xanthinderivaten zur Reduktion der pathologischen Hyperreagibilität eosinophiler Granulozyten, neue Xanthinverbindungen und Verfahren zu deren Herstellung
DEP4411660.8 1994-04-05

Publications (2)

Publication Number Publication Date
KR970702044A KR970702044A (ko) 1997-05-13
KR100373948B1 true KR100373948B1 (ko) 2003-06-09

Family

ID=6514636

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960705541A KR100373948B1 (ko) 1994-04-05 1995-03-21 호산성과립구의병적인과반응성을감소시키기위한크산틴유도체를포함하는약제학적조성물,신규한크산틴화합물및이의제조방법

Country Status (11)

Country Link
EP (1) EP0758239A1 (fr)
JP (1) JPH09510983A (fr)
KR (1) KR100373948B1 (fr)
CN (1) CN1098686C (fr)
AU (1) AU695488B2 (fr)
CA (1) CA2187081A1 (fr)
DE (1) DE4411660A1 (fr)
HU (1) HUT74732A (fr)
RU (1) RU2159617C2 (fr)
UA (1) UA39136C2 (fr)
WO (1) WO1995026727A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985592A (en) * 1997-06-05 1999-11-16 Dalhousie University Uses for pentoxifylline or functional derivatives/metabolites thereof
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
WO1999049865A1 (fr) * 1998-03-31 1999-10-07 Mayo Foundation For Medical Education And Research Utilisation d'inhibiteurs du facteur d'activation des plaquettes sanguines (paf) pour entraver une activation ou une degranulation eosinophilique declenchee par l'interleukine 5
JP2005529934A (ja) 2002-05-31 2005-10-06 シェーリング　コーポレイション キサンチンホスホジエステラーゼｖインヒビターおよびその前駆物質を調製するプロセス
SI1509525T1 (sl) * 2002-05-31 2006-12-31 Schering Corp Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8918297D0 (en) * 1989-08-10 1989-09-20 Beecham Group Plc Novel treatment
DD298051A5 (de) * 1989-08-16 1992-02-06 ��@���������@�������k�� Verfahren zur herstellung eines therapeutischen agens zur behandlung von verdauungskrankheiten
GB9023783D0 (en) * 1990-11-01 1990-12-12 Celltech Ltd Pharmaceutical product
IL100195A0 (en) * 1990-11-30 1992-08-18 Hoechst Roussel Pharma Use of xanthines for the preparation of a medicament having immuno suppressing activity
WO1993003728A1 (fr) * 1991-08-27 1993-03-04 Temple University Of The Commonwealth System Of Suppression par la xanthine de l'activation d'antigenes des lymphocytes t ou b
IL99368A (en) * 1991-09-02 1996-01-19 Teva Pharma Preparations for the treatment of psoriasis and atopic dermatitis, which contain the result of xanthine
US5473070A (en) * 1992-11-16 1995-12-05 Cell Therapeutics, Inc. Substituted long chain alcohol xanthine compounds

Also Published As

Publication number Publication date
EP0758239A1 (fr) 1997-02-19
KR970702044A (ko) 1997-05-13
RU2159617C2 (ru) 2000-11-27
UA39136C2 (uk) 2001-06-15
DE4411660A1 (de) 1995-10-12
HU9602712D0 (en) 1996-11-28
JPH09510983A (ja) 1997-11-04
CN1098686C (zh) 2003-01-15
AU695488B2 (en) 1998-08-13
AU1951095A (en) 1995-10-23
CA2187081A1 (fr) 1995-10-12
WO1995026727A1 (fr) 1995-10-12
CN1145029A (zh) 1997-03-12
HUT74732A (en) 1997-02-28

Similar Documents

Publication Publication Date Title
JP4045070B2 (ja) キノリン誘導体
FI89921C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara tertiaera hydroxialkylxantiner
KR100531964B1 (ko) 말단아민화알킨올측쇄를갖는크산틴화합물
IL138160A (en) Quinoline derivatives
JPH0692407B2 (ja) Ｎ▲上６▼−ジ置換プリン誘導体、その製法及び該誘導体を含有するアレルギ−性疾患の治療剤
EP1556031A2 (fr) Chromones et derives de chromones, et utilisations de ceux-ci
CZ286816B6 (en) Benzimidazole derivatives, and pharmaceutical preparations in which they are comprised and their use for preparing medicaments
KR20010071491A (ko) 퀴놀린 유도체
IE47884B1 (en) Xanthine derivatives having antiallergic activity and pharmacological preparations containing them
DE2740588A1 (de) Imidazo- eckige klammer auf 1,2-a eckige klammer zu -chinolin-2-carbon- saeuren und deren derivate sowie pharmazeutische zubereitungen, die diese verbindungen enthalten
EP0369744A2 (fr) Dérivés de Xanthine, procédé pour leur préparation et compositions pharmaceutiques les contenant
KR100373948B1 (ko) 호산성과립구의병적인과반응성을감소시키기위한크산틴유도체를포함하는약제학적조성물,신규한크산틴화합물및이의제조방법
US8193200B2 (en) Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease
JP3436547B2 (ja) 頭蓋脳外傷後の二次的神経細胞損傷および機能疾患を治療するためのキサンチン誘導体の使用
KR20240142481A (ko) 엑토뉴클레오티드 피로포스파타제-포스포디에스테라제 1 (enpp1) 억제제 및 그의 용도
CN113214097B (zh) 治疗阿尔茨海默病的化合物
US20020010333A1 (en) Use of xanthine derivatives for reducing the pathological hyperreactivity of eosinophilic granulocytes, novel xanthine compounds and process for their preparation
CN114516843B (zh) 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
JPH0615472B2 (ja) アレルギー疾患治療剤
CA3223475A1 (fr) Nouveau derive de benzopyrane et son utilisation
JPH04279586A (ja) キサンチン誘導体
JPS60142986A (ja) プリン誘導体
JPH03218378A (ja) キサンチン誘導体
JPH0656833A (ja) 血液循環の中断による神経損傷を治療するためのキサンチン誘導体の使用
DE19622734A1 (de) Xanthinverbindungen mit terminal aminierten Alkinol-Seitenketten

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee